Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6185MR)

This product GTTS-WQ6185MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6185MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11701MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ6310MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ15252MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ15894MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ3855MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ9523MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ17MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ2113MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW